| Literature DB >> 33068786 |
Marc Fenster1, Quazim A Alayo2, Aava Khatiwada3, Wenfei Wang4, Christina Dimopoulos5, Alexandra Gutierrez3, Matthew A Ciorba3, George P Christophi6, Robert P Hirten7, Christina Ha8, Poonam Beniwal-Patel9, Benjamin L Cohen10, Gaurav Syal8, Andres Yarur9, Anish Patel11, Jean-Frederic Colombel7, Joel Pekow4, Ryan C Ungaro7, David T Rubin4, Parakkal Deepak12.
Abstract
The safety and efficacy of tofacitinib in Crohn's disease (CD) has been studied in 2 phase II trials in patients with moderate-to-severe CD with no new safety signals observed, but no significant difference from placebo in the primary efficacy endpoint of clinical response.1-3 However, post hoc analyses and smaller studies have observed clinical and biologic response to tofacitinib in patients with CD.2,4,5 There is a paucity of real-world effectiveness and safety data for tofacitinib in non-Food and Drug Administration label usage in patients with CD and patients with inflammatory bowel disease-unclassified (IBD-U).Entities:
Mesh：
Substances：
Year: 2020 PMID： 33068786 PMCID： PMC8044250 DOI： 10.1016/j.cgh.2020.10.025
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN： 1542-3565 Impact factor: 13.576